Tag
This review synthesizes evidence on the impact of kidney function, BMI, and anemia on plasma p-tau217 diagnostic accuracy, advocating for subgroup-specific cutoff strategies to improve clinical outcomes.
This study highlights how comorbid Alzheimer’s and FTLD neuropathologies manifest through unique neuropsychiatric profiles, such as increased anxiety and personality changes, providing clinicians with vital clues for identifying mixed
This pilot randomized clinical trial investigated low-dose lithium for Mild Cognitive Impairment (MCI). While primary outcomes regarding cognition and neuroimaging were not statistically significant, the study established the intervention&#
A multi-cohort study demonstrates that women with amyloid-β pathology show higher plasma p-tau217 levels and faster tau PET accumulation than men, providing a biological basis for their increased risk of rapid cognitive decline in preclinic
A large-scale longitudinal study reveals that over 80% of community-dwelling older adults harbor mixed neuropathologies, identifying five distinct profiles that dictate specific cognitive decline trajectories, with ADNC and LATE-NC clusters
Standard single cutoffs for plasma p-tau217 are significantly confounded by kidney function, BMI, and anemia. A new study demonstrates that subgroup-specific or double-cutoff strategies markedly improve diagnostic accuracy and cost-effectiv
The Phase 2b ELAD trial investigated liraglutide’s efficacy in mild-to-moderate Alzheimer’s disease. While it failed its primary metabolic endpoint, significant improvements in executive function suggest a nuanced role for GLP-1
Recent clinical evidence reveals that soluble amyloid-beta oligomers, rather than traditional plaques, drive glucose dysregulation and depression in early Alzheimer’s disease. Crucially, these associations are modulated by tau pathology, su
A Phase 2 trial of crenezumab in cognitively unimpaired PSEN1 mutation carriers found no significant clinical benefit over 5-8 years, suggesting that robust amyloid plaque removal may be essential for disease modification in early-stage Alz
A comprehensive multi-cohort proteomic study identifies Oligodendrocyte Myelin Glycoprotein (OMG) as a causal biomarker for neurodegenerative resiliency, linking its peripheral abundance to axonal integrity and reduced risk of dementia and
This study establishes patient-centered amyloid PET thresholds for tauopathy onset, revealing that age and sex significantly influence the transition from amyloidosis to tau accumulation. These personalized cut-offs better predict cognitive
A longitudinal study reveals that over 5% of patients with MCI or dementia develop new indications for anticoagulants or thrombolytics within a year, complicating the use of anti-amyloid monoclonal antibodies due to increased intracranial h
Emerging evidence confirms that air pollution, particularly PM2.5 and NO2, is directly associated with Alzheimer’s neuropathology, structural brain changes, and cognitive decline. New research highlights that these effects are partially med
This study demonstrates that the mismatch between tau burden and clinical symptoms identifies individuals with non-AD copathology or cognitive resilience. These findings offer a precision medicine framework for predicting disease trajectori
Blarcamesine shows potential in slowing early Alzheimer’s progression, but questions about trial data robustness and transparency have been raised.
The VALAD randomized clinical trial found that valacyclovir did not improve outcomes in patients with early symptomatic Alzheimer’s and HSV seropositivity. Instead, patients receiving the antiviral showed significantly greater cognitive dec
A pivotal longitudinal study demonstrates that plasma p-tau217 and GFAP accurately predict amyloid-β and tau deposition, cognitive decline, and dementia risk in adults with Down syndrome, offering a transformative, non-invasive tool for cli
Longitudinal tau-PET accumulation follows distinct regional patterns across biological AD stages; aligning trial inclusion and outcome ROIs to baseline tau stage can substantially reduce sample sizes and improve power for disease-modifying
Functional connectivity reliably predicts spatial and temporal tau propagation patterns across atypical Alzheimer’s disease variants, underpinning personalized approaches to diagnosis and therapy.
A phase 2a randomized trial found low‑dose IL‑2 given every 4 weeks was safe, expanded regulatory T cells, altered peripheral inflammatory mediators, increased CSF Aβ42, stabilized NfL, and trended toward slower cognitive decline in mild–mo
